Grade 3/4 adverse event costs of immuno-oncology combination therapies for previously untreated advanced renal cell carcinoma

HIGHLIGHTS

SUMMARY

All-cause and treatment-related grade 3/4 AEs with corresponding any grade AEs that occurred in at least 20% of patients in the nivolumab plus ipilimumab arm (CheckMate 214), nivolumab plus cabozantinib arm (CheckMate 9ER), pembrolizumab plus axitinib arm (KEYNOTE-426), and pembrolizumab plus lenvatinib arm (KEYNOTE-581) were considered in the cost calculation. The combination of nivolumab plus cabozantinib was granted FDA approval in January 2021 for treatment-naïve patients with aRCC in any-risk group based on the results of the CheckMate 9ER trial (NCT03141177)14 wherein allcause grade 3 . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.